Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
sotevtamab
- Development stage
- Phase 2
- Lead developer
- Alethia Biotherapeutics
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Administration
- Intravenous
01
Overview
Sotevtamab is a humanized IgG2 monoclonal antibody that targets clusterin, specifically an epithelial-to-mesenchymal transition (EMT)-inducing form of secreted clusterin. It acts as a clusterin inhibitor and is being developed primarily for cancer therapy, including colorectal cancer and non-small cell lung cancer. Sotevtamab inhibits the invasion of certain cancer cells, such as PANC-1 pancreatic cancer cells, by blocking EMT processes. The drug is under investigation in combination with standard chemotherapy regimens like FOLFOX to enhance tumor shrinkage prior to surgical resection in metastatic colorectal cancer patients. Sotevtamab was originally developed by the National Research Council Biotechnology Research Institute and further advanced by Alethia BioTherapeutics[1][2][3][7].
- Other names
- Anti-clusterin monoclonal antibody
02
Targets
CLU (Clusterin)
Beyond the preview
Go deeper on sotevtamab.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on sotevtamab.